Excluding nonrecurring items, the Indianapolis-based drugmaker posted adjusted earnings of 10 cents a share, beating Zacks consensus estimate of a loss of 11 cents a share.
Eli Lilly and Co.’s hot-selling diabetes drug, Mounjaro, will now be sold for a second use, chronic weight management, using a separate brand name, Zepbound.
The Indianapolis-based drug company is ramping up manufacturing capacity to avoid possible shortages and to meet potentially huge demand in a nation where more than 40% of adults are classified as obese.
The current water study is examining the art of the possible—if appropriate need should exist in the future to move water from the Lafayette region to central Indiana. Indiana is blessed with more than adequate water resources; they’re just not always precisely where we need them.
The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease—but not diabetes.
Point has a pipeline of clinical and preclinical-stage compounds in development for the treatment of cancer using radiopharmaceutical isotopes that hold the promise of delivering targeted treatments to cancer patients.
The move comes as the Indiana Economic Development Corp. faces questions about its plan to tap the Wabash River aquifer and withdraw as much as 100 million gallons per day for an advanced manufacturing district in central Indiana.
The live-work-play campus has been picked to join a new national network designed to connect researchers, entrepreneurs and investors to accelerate the development of health care products and services and speed up health care innovations.
Consideration of a pipeline to pump massive amounts of water from Lafayette to the LEAP Innovation and Research District in Lebanon is revealing major gaps in Indiana’s water-rights laws, some stakeholders say.
The two companies have been battling for years over patents for migraine headache drugs—Emgality for Lilly and Anjovy for Teva. Both drugs are once-monthly injections and were approved 13 days apart in September 2018.
The Indiana Economic Development Corp. is one of seven sponsors of a two-day event happening against the backdrop of the United Nations Climate Change Conference in Dubai.
The company, Carmot Therapeutics, has numerous drugs under development. Its lead asset is a once-a-week injection that is in mid-stage development for the treatment of obesity.
Mundo Sanchez, CFO of refrigerated-trucking company Renewable Transport Services, said his role as chief financial officer extends far beyond financial reporting.
